BioSphere requests US trial for fibroid treatment:
This article was originally published in Clinica
BioSphere Medical has filed an investigational device exemption application with the FDA to begin US trials of its microsphere embolisation technology as a treatment for uterine fibroids. The Embosphere microspheres, which has shown potential for uterine artery embolisation in animal studies, could provide a less invasive alternative to surgery for women with the condition, said the Marlborough, Massachusetts-based company. The product is already CE-marked in Europe and has been submitted to the FDA for treating hypervascularised tumours and arteriovenous malformations.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Commissioner Hahn’s tweet announcing a return to inspections, while not a new policy, may be signal that FDA understands sponsor concerns with the agency’s limited ability to conduct onsite inspections. Effort may be aimed at reassuring industry even as CRLs related to manufacturing increase.
Rushed final rule seeking to impose draconian cuts on drug reimbursement rates in the Medicare Part B program is certain to face legal and political obstacles. But the data included on international price benchmarks will still have an impact.